Related references
Note: Only part of the references are listed.Sa1902 Short- and Long-Term Outcomes of Infliximab Dose Intensification in Patients With Ulcerative Colitis
Carlos Taxonera et al.
GASTROENTEROLOGY (2015)
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
Bella Ungar et al.
GUT (2014)
Meta-analysis: rapid infliximab infusions are safe
H. C. Neef et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
Kavinderjit S. Nanda et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti-TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease
Jonathan P. Terdiman et al.
GASTROENTEROLOGY (2013)
Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease
Abdenour Babouri et al.
JOURNAL OF CROHNS & COLITIS (2013)
Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis
E. Rostholder et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Direct Health Care Insurer and Out-of-Pocket Expenditures of Inflammatory Bowel Disease: Evidence from a US National Survey
Candace Gunnarsson et al.
DIGESTIVE DISEASES AND SCIENCES (2012)
Long-term infliximab maintenance therapy for ulcerative colitis: The ACT-1 and-2 extension studies
Walter Reinisch et al.
INFLAMMATORY BOWEL DISEASES (2012)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
Axel Dignass et al.
JOURNAL OF CROHNS & COLITIS (2012)
Tolerability of Shortened Infliximab Infusion Times in Patients With Inflammatory Bowel Diseases: A Single-Center Cohort Study
Christine Breynaert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Inflammatory Bowel Disease-Attributable Costs and Cost-effective Strategies in the United States: A Review
K. T. Park et al.
INFLAMMATORY BOWEL DISEASES (2011)
Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee
Asher Kornbluth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Are Accelerated Infliximab Infusions Safe in Patients with Inflammatory Bowel Disease?
Shivaram Bhat et al.
INFLAMMATORY BOWEL DISEASES (2010)
Infliximab administered with shortened infusion times in a specialized IBD infusion unit: A prospective cohort study
Gert Van Assche et al.
JOURNAL OF CROHNS & COLITIS (2010)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
A. Dignass et al.
JOURNAL OF CROHNS & COLITIS (2010)
Management of Crohn's Disease in Adults
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease
Donnellan F. Clare et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2009)
M1707 One Hour Infliximab Infusion Can Replace Two Hour Infusion in Maintenance Treatment of Crohns Disease Without Shortcomings, in Patients Treated for Up to Three Years
Ragnar Befrits et al.
GASTROENTEROLOGY (2008)
Infliximab dose intensification in Crohn's disease
Miguel Regueiro et al.
INFLAMMATORY BOWEL DISEASES (2007)
Shortening infusion times for infliximab administration
MH Buch et al.
RHEUMATOLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Feasibility of 1 hour infliximab infusions
RF van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-α
H Mitoma et al.
GASTROENTEROLOGY (2004)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Long-term Treatment of Rectovaginal Fistulas in Crohn's Disease: Response to Infliximab in the ACCENT II Study
Bruce E. Sands et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway
A Lügering et al.
GASTROENTEROLOGY (2001)
Share Paper
